Continuous hemodiafiltration with a cytokine-adsorbing hemofilter for sepsis

Blood Purification

Volumn 34, Issue 2, 2012, Pages 164-170

  Hirasawa, Hiroyuki ^a   Oda, Shigeto ^a   Nakamura, Masataka ^a   Watanabe, Eizo ^a   Shiga, Hidetoshi ^b   Matsuda, Kenichi ^c  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

^c UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Alarmin; AN69ST hemofilter; Continuous hemodiafiltration; Cytokine adsorbing hemofilter; Direct hemoperfusion with polymyxin B immobilized column; Endotoxin; High volume continuous hemofiltration; Hypercytokinemia; Pathogen associated molecular patterns; Polymethyl methacrylate hemofilter

Indexed keywords

DOUBLE STRANDED RNA; FLAGELLIN; PEPTIDOGLYCAN; POLY(METHYL METHACRYLATE); POLYMYXIN B;

ACUTE KIDNEY FAILURE; ARTICLE; BACTEREMIA; BLOOD FILTER; BLOOD LEVEL; CLINICAL TRIAL (TOPIC); CONTINUOUS HEMODIAFILTRATION; CRITICALLY ILL PATIENT; CYTOKINE ADSORBING HEMOFILTER; CYTOKINE STORM; GENE THERAPY; GRAM POSITIVE BACTERIUM; HEMODIAFILTRATION; HEMOFILTRATION; HEMOPERFUSION; HUMAN; HYPERGLYCEMIA; INSULIN TREATMENT; MULTIPLE ORGAN FAILURE; PLASMAPHERESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SALVAGE THERAPY; SEPSIS; SEPTIC SHOCK;

ADSORPTION; CYTOKINES; HEMODIAFILTRATION; HUMANS; POLYMETHYL METHACRYLATE; POLYMYXIN B; SEPSIS;

EID: 84867975301     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000342379     Document Type: Article

References (36)

1. Corriveau CC, Danner RL: Endotoxin as a therapeutic target in septic shock. Infect Agents Dis 1993; 2: 35-43.
2. Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, Malcangi V, Petrini F, Volta G, Pallavicini FMB, Rottoli F, Giunta F, Ronco C: Early use of polymyxin B hemoperfuson in abdominal septic shock. The EUPHAS randomized controlled trial. JAMA 2009; 301: 2445-2452.
3. Abe R, Oda S, Sadahiro T, Nakamura M, Hirayama Y, Tateishi Y, Shinozaki K, Hirasawa H: Gram-negative bacteremia induces greater magnitude of inflammatory response than gram-negative bacteremia. Crit Care 2010; 14:R27.
4. Cinel I, Opal SM: Molecular biology of inflammation and sepsis. A primer. Crit Care Med 2009; 37: 291-304.
5. Tracey KJ: Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest 2007; 117: 289-296.
6. Nakamura M, Oda S, Sadahiro T, Watanabe E, Abe R, Nakada T, Morita Y, Hirasawa H: Correlation between high blood IL-6 level, hyperglycemia, and glucose control in septic patients. Crit Care 2012; 16:R58.
7. Di Carlo JV, Alexander SR: Hemofiltration for cytokine-driven illnesses: The mediator delivery hypothesis. Int J Artif Organs 2005; 28: 777-786.
8. Nakada T, Hirasawa H, Oda S, Shiga H, Matsuda K: Blood purification for hypercytokinemia. Transfusion Apher Sci 2006; 35: 253-264.
9. Kobe Y, Oda S, Matsuda K, Nakamura M, Hirasawa H: Direct hemoperfusion with cytokine-Adsorbing device for the treatment of persistent or severe hypercytokinemia: A pilot study. Blood Purif 2007; 25: 446-453.
10. Payen D, Mateo J, Cavaillon JM, Fraisse F, Floriot C, Vicaut E: Impact of continuous venovenous hemofiltration on organ failure during early phase of severe sepsis. A randomized controlled trial. Crit Care Med 2009; 37: 803-810.
11. Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P, La Greca G: Effects of different doses in continuous veno-venous haemofiltration on outcome of acute renal failure: A prospective randomized trial. Lancet 2000; 356: 26-30.
12. Cornejo R, Downey P, Castro R, Romero C, RegueiraT, Vega J, Castillo L, Andresen M, Dougnac A, Bugedo G, Hernandez G: Highvolume hemofiltration as salvage therapy in severe hyperdynamic septic shock. Intensive Care Med 2006; 32: 713-722.
13. Honore PM, Joannes-Boyau O, Boer W, Collin V: High-volume hemofiltration in sepsis and SIRS: Current concepts and future prospects. Blood Purif 2009; 28: 1-11.
14. The RENAL Replacement Therapy Study Investigators: Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 2009; 361: 1627-1638.
15. Brochard L, Abroug F, Brenner M, Broccard AF, Danner RL, Ferrer M, Laghi F, Magder S, Papazian L, Pelosi P, Polderman KH: An official ATS/ERS/ESICM/SCCM/SRLF statement: Prevention and management of acute renal failure in the ICU patient. An international consensus conference in intensive care medicine. Am J Respir Crit Care Med 2010; 181: 1128-1155.
16. Kellum JA, Song M, Venkataraman R: Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor- - B DNA binding, and improves short-Term survival in lethal endotoxemia. Crit Care Med 2004; 32: 801-805.
17. Rimmele T, Assadi A, Cattenoz M, Desebbe O, Lambert C, Boselli E, Goudable J, Etienne J, Chassard D, Bricca G, Allaouchiche B: High-volume haemofiltration with a new haemofiltration membrane having enhanced adsorption properties in septic pigs. Nephrol Dial Transplant 2009; 24: 421-427.
18. Haase M, Silvester W, Uchino S, Goldsmith D, Davenport P, Tipping P, Boyce N, Bellomo R: A pilot study of high-Adsorption hemofiltration in human septic patients. Int J Artif Organs 2007; 30: 108-117.
19. Hirasawa H: Indications for blood purification in critical care. Contrib Nephrol 2010; 166: 21-30.
20. Yamashita AC, Tomisawa N: Importance of membrane materials for blood purification devices in critical care. Transfusion Apher Sci 2009; 40: 23-31.
21. Hirayama Y, Oda S, Wakabayasi K, Sadahiro T, Nakamura M, Watanabe E, Tateishi Y: Comparison of interleukin-6 removal properties among hemofilters consisting of varying membrane materials and surface areas: An in vitro study. Blood Purif 2011; 31: 18-25.
22. Matsuda K, Moriguchi T, Harii N, Goto J: Comparison of efficacy between continuous hemodiafiltration with a PMMA membrane hemofilter and a PAN membrane hemofilter in the treatment of a patient with septic acute renal failure. Transfusion Apher Sci 2009; 40: 49-53.
23. Ronco C, Kellum JA, Bellomo R, House AA: Potential interventions in sepsis-related acute renal failure. Clin J Am Soc Nephrol 2008; 3: 531-544.
24. Hirasawa H, Oda S, Matsuda K: Continuous hemodiafiltration with cytokine-Adsorbing hemofilter in the treatment of severe sepsis and septic shock. Contrib Nephrol 2007; 156: 365-370.
25. Nakada T, Oda S, Matsuda K, Sadahiro T, Nakamura M, Abe R, Hirasawa H: Continuous hemodiafiltration with PMMA hemofilter in the treatment of patients with septic shock. Mol Med 2008; 257-263.
26. Nakamaura M, Oda S, Sadahiro T, Hirayama Y, Watanabe E, Tateishi Y, Nakada T, Hirasawa H: Treatment of severe sepsis and septic shock by CHDF using a PMMA membrane hemofilter as a cytokine modulator. Contrib Nephrol 2010; 166: 73-82.
27. Matsumura Y, Oda S, Sadahiro T, Nakamura M, Hirayama Y, Watanabe E, Abe R, Nakada T, Tateishi Y, Oshima T, Shinozaki K, Hirasawa H: Treatment of septic shock with continuous HDF using 2 PMMA hemofilters for enhanced intensity. Int J Artif Organs 2012; 35: 3-14.
28. Watanabe E, Hirasawa H, Oda S, Matsuda K, Hatano M, Tokuhisa T: Extremely high interleukin-6 blood levels and outcome in the critically ill are associated with tumor necrosis factor- And interleukin-1-related gene polymorphisms. Crit Care Med 2005; 33: 89-97.
29. Martin E, Cruz DN, Monti G, Casella G, Vesconi S, Ranieri VM, Ronco C, Antonelli M: Endotoxin removal: How far from the evidence? The EUPHAS 2 project. Contrib Nephrol 2010; 167: 119-125.
30. Sakamoto Y, Mashiko K, Obata T, Matsumoto H, Hara Y, Kutsukata N, Yamamoto Y: Effectiveness of continuous hemodiafiltration using a polymehtylmethacrylate membrane hemofilter after polymyxin B-immobilized fiber column therapy of septic shock. ASAIO J 2008; 54: 129-132.
31. Honore PM, Jamez J, Wauthier M, Lee PA, Dugernier T, Pirenne B, Hanique G, Matson JR: Prospective evaluation of short-Term, high-volume isovolemic hemofiltration on the course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med 2000;28:3581-3587.
32. Piccinni P, Dan M, Carraro R, Lieta E, Marafon S, Zamperetti N, Brendolan A, D'Intini V, Tetta C, Bellomo R, Ronco C: Early isovolemic haemofiltration in oliguric patients with septic shock. Intensive Care Med 2006;32:80-86.
33. Boussekey N, Chiche A, Faure K, Devos P, Guery B, d'Escrivan T, Georges H, Leroy O: A pilot study comparing high and low volume hemofiltration on vasopressor use in septic shock. Intensive Care Med 2008;34: 1646-1653.
34. Vincent JL, Laterre PE, Cohen J, Burchardi H, Bruining H, Lerma FA, Wittebole X, De Backer D, Brett S, Marzo D, Nakamura H, John S: A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge n patients with severe sepsis secondary to intra-Abdominal infection. Shock 2005;23:400-405.
35. Kojika M, Sato N, Yaegashi Y, Suzuki Y, Suzuki K, Nakae H, Endo S: Endotoxin adsorption therapy for septic shock using polymyxin B-immobilized fibers (PMX): Evaluation by high-sensitivity endotoxin assay and measurement of the cytokine production capacity. Ther Apher Dial 2006;10:12-18.
36. Nakamura T, Sugaya T, Koide H: Urinary liver-Type fatty acid-binding protein in septic shock: Effect of polymyxin B-immobilized fiber hemoperfusion. Shock 2009;31:454-459.